cDNA microarray results of Pim-1 expression from several human myeloid leukemia-derived cell lines in response to FLT3 inhibition
. | 4-h inhibition with CEP-701 . | 4-h release after 4-h inhibition . | 8-h inhibition with CEP-701 . | 8-h release after 8-h inhibition . |
|---|---|---|---|---|
| EOL-1, fold change | 0.16 | 0.34 | 0.17 | 0.40 |
| MOLM-14, fold change | 0.31 | 0.48 | 0.45 | 0.70 |
| MV4-11, fold change | 0.27 | 0.41 | 0.26 | 0.31 |
. | 4-h inhibition with CEP-701 . | 4-h release after 4-h inhibition . | 8-h inhibition with CEP-701 . | 8-h release after 8-h inhibition . |
|---|---|---|---|---|
| EOL-1, fold change | 0.16 | 0.34 | 0.17 | 0.40 |
| MOLM-14, fold change | 0.31 | 0.48 | 0.45 | 0.70 |
| MV4-11, fold change | 0.27 | 0.41 | 0.26 | 0.31 |
The table shows the fold difference of raw data of Pim-1 signals in CEP-701-treated cells relative to untreated controls.
P < .02, derived from 1-sided pairwise t test from 6 independent experiments (4-h inhibition versus 4-h release after 4-h inhibition and 8-h inhibition versus 8-h release after 8-h inhibition from EOL-1, MOLM-14, and MV4-11). The P value was calculated from log-transformed data.